Ranbaxy merger showing sharp cons as well as pros for Sun Pharma

The merger with Ranbaxy by Sun Pharmaceuticals has given the company scale to move up the food chain in the industry but has also come at a cost to the enlarged entity, Business Today reports. The deal made Sun the world's fifth-largest generic drug maker and moved it up the corporate rankings in India but tied the company to Ranbaxy plants that have been banned by the U.S. FDA for not meeting quality standards. Legal fees, high staff costs and a one-time writedown of about $94 million hurt profitability, as did problems at one of the company's U.S. plants and declining prices in several categories, Business Today said. Report

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.